Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Shares Outstanding (Weighted Average) (2022 - 2025)

Historic Shares Outstanding (Weighted Average) for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $73.4 million.

  • Phathom Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1356.78% to $73.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.4 million, marking a year-over-year increase of 1356.78%. This contributed to the annual value of $63.2 million for FY2024, which is 2317.67% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $73.4 million for Q3 2025, which was up 1356.78% from $72.5 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $73.4 million during Q3 2025, with a 5-year trough of $38.0 million in Q1 2022.
  • In the last 4 years, Phathom Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $56.8 million in 2023 and averaged $54.4 million.
  • Examining YoY changes over the last 5 years, Phathom Pharmaceuticals' Shares Outstanding (Weighted Average) showed a top increase of 4626.99% in 2023 and a maximum decrease of 1135.1% in 2023.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $39.1 million in 2022, then surged by 31.11% to $51.3 million in 2023, then grew by 23.18% to $63.2 million in 2024, then increased by 16.18% to $73.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $73.4 million in Q3 2025, compared to $72.5 million in Q2 2025 and $72.0 million in Q1 2025.